Concert Pharmaceuticals, Inc. (CNCE) Financial Statements (2024 and earlier)

Company Profile

Business Address 65 HAYDEN AVENUE
LEXINGTON, MA 02421
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2022
MRQ
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 141,600130,000106,400153,300203,20096,200
Cash and cash equivalents 141,63677,20253,04317,77027,66540,555
Short-term investments 1,46354,73558,770143,069175,50055,630
Other undisclosed cash, cash equivalents, and short-term investments (1,499)(1,937)(5,413)(7,539)3515
Receivables 2183,17733257115527
Contract with customer, asset, after allowance for credit loss    16,000
Deferred costs 15 143   
Other undisclosed current assets 8,4969,5479,98010,2782,3791,502
Total current assets: 150,329142,724116,855180,149205,73497,729
Noncurrent Assets
Operating lease, right-of-use asset 8,5858,9689,252
Property, plant and equipment 5,2426,3637,7538,9192,1652,199
Restricted cash and investments 1,1571,1571,1571,1571,557400
Other noncurrent assets 35196 3467
Other undisclosed noncurrent assets   2,3582,3222,246 
Total noncurrent assets: 14,98716,53920,61612,3986,0022,666
TOTAL ASSETS: 165,316159,263137,471192,547211,736100,395
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 7,3174,6294,9655,8604,3783,366
Taxes payable   39046 
Employee-related liabilities3,6173,6903,2223,0672,7972,010
Accounts payable 2,6062308811,277658545
Accrued liabilities 1,0947098621,126877811
Deferred revenue   7,783
Debt   268   
Deferred revenue and credits1,5461,274
Contract with customer, liability1,413
Other undisclosed current liabilities 8,8035,5494,2521,476521930
Total current liabilities: 16,12010,17817,2688,7496,4455,570
Noncurrent Liabilities
Long-term debt and lease obligation: 13,91015,06515,996   
Liabilities, other than long-term debt 7,6232,8582,75011,9708,8599,231
Deferred revenue and credits8,8599,231
Accounts payable and accrued liabilities 28108    
Deferred revenue 7,5952,7502,750
Contract with customer, liability9,120
Deferred rent credit    2,850
Operating lease, liability 13,91015,06515,996
Other undisclosed noncurrent liabilities 15,438  4,088  
Total noncurrent liabilities: 36,97117,92318,74616,0588,8599,231
Total liabilities: 53,09128,10136,01424,80715,30414,801
Equity
Equity, attributable to parent 112,225131,162101,457167,740196,43285,594
Common stock 343124232322
Additional paid in capital 461,765400,636296,145284,369273,059257,461
Accumulated other comprehensive loss (76)(58)(31)(137)(407)(7)
Accumulated deficit (349,498)(269,447)(194,681)(116,515)(76,243)(171,882)
Total equity: 112,225131,162101,457167,740196,43285,594
TOTAL LIABILITIES AND EQUITY: 165,316159,263137,471192,547211,736100,395

Income Statement (P&L) ($ in thousands)

9/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues 32,5787,9021,07710,505143,891174
Revenue, net143,891174
Gross profit: 32,5787,9021,07710,505143,891174
Operating expenses (110,086)(80,549)(80,092)(66,089)(51,242)(51,341)
Operating income (loss): (77,508)(72,647)(79,015)(55,584)92,649(51,167)
Nonoperating income 461,2022,9992,7994,122447
Investment income, nonoperating 461,2022,9872,7871,336447
Other nonoperating income   12122,786 
Interest and debt expense     (1,432) 
Income (loss) from continuing operations before income taxes: (77,462)(71,445)(76,016)(52,785)95,339(50,720)
Income tax expense (benefit)  85 (313)300 
Income (loss) from continuing operations: (77,462)(71,360)(76,016)(53,098)95,639(50,720)
Income (loss) before gain (loss) on sale of properties:(77,462)(71,360)(76,016)(53,098)95,639(50,720)
Net income (loss): (77,462)(71,360)(76,016)(53,098)95,639(50,720)
Other undisclosed net loss attributable to parent (2,589)(3,406)(2,150)(2,926)  
Net income (loss) attributable to parent: (80,051)(74,766)(78,166)(56,024)95,639(50,720)
Undistributed earnings (loss) allocated to participating securities, basic     (444)
Net income (loss) available to common stockholders, basic: (80,051)(74,766)(78,166)(56,024)95,195(50,720)
Other undisclosed net income available to common stockholders, diluted     15 
Net income (loss) available to common stockholders, diluted: (80,051)(74,766)(78,166)(56,024)95,210(50,720)

Comprehensive Income ($ in thousands)

9/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net income (loss): (77,462)(71,360)(76,016)(53,098)95,639(50,720)
Other comprehensive income (loss)     95,239(50,709)
Comprehensive income (loss): (77,462)(71,360)(76,016)(53,098)190,878(101,429)
Other undisclosed comprehensive loss, net of tax, attributable to parent (2,607)(3,433)(2,044)(2,656)  
Comprehensive income (loss), net of tax, attributable to parent: (80,069)(74,793)(78,060)(55,754)190,878(101,429)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: